Top-Thema

24.11.17
ROUNDUP/Aktien New York Schluss: Freundlich - S&P 500 endet erstmals über 2600

Coloplast Delivers On Ambitious Targets With Solid Interim Report

Mittwoch, 13.08.2014 12:00 von PR Newswire

PR Newswire

MINNEAPOLIS, Aug. 13, 2014 /PRNewswire/ -- Danish medical device company Coloplast delivered revenue of USD* 1,654 million (DKK 9,214 million) and 9% organic growth in the first nine months of the 2013/14 financial year. Q3 organic growth was 8%.

EBIT before special items was up by 13% to USD 547 million (DKK 3,047 million). The EBIT margin before special items was 33% against 31% in 9M 2012/13.

Delivering on ambitious targets
"I'm pleased with the solid financial results we are announcing today. We are continuing our string of healthy growth in all business areas and in all regions, and our consolidated profit is matching the high expectations we have for our company," said Coloplast CEO Lars Rasmussen.

Global sales growth by business area was as follows: Ostomy Care 8%, Continence Care 11%, Urology Care 10% and Wound & Skin Care 10%. Coloplast grew its European business by 6%, Other Developed Markets by 10% and Emerging Markets by 24%.

Consumer centered strategy
Senior Vice President, Chronic Care US, Ed Veome says: "The US is an important market for Coloplast and we have invested to grow our business as we see great potential. It is very encouraging that we have seen strong sales performance in our continence and ostomy care product lines."

"We're pursuing a strategy that puts the consumer in the center. The majority of our users in the US have overcome critical conditions that led them to our products, and we want to help them return to their normal lives. We can only do that by listening and responding to their needs."

Coloplast employs more than 500 people in the US and has it US headquarter in Minneapolis, Minnesota. Globally Coloplast employs more than 9.000 with its products being sold in more than 100 countries around the world. Coloplast is listed on the Copenhagen Stock Exchange, part of the NASDAQ OMX Group and has a market cap of around USD 18 billion (DKK 100 billion).

Financial guidance for 2013/14 unchanged
Following the Q3 interim report, Coloplast continues to expect full-year organic revenue growth of about 9% and of about 7% in DKK. The company continues to expect the EBIT margin before special items to be 33-34% at constant exchange rates and about 33% in DKK.

For further information, click here to read the Q3 Interim Report.

*At exchange rate USD/DKK 5,57

www.coloplast.com


 


Financial highlights and key ratios






Financial highlights
and key ratios
DKKm

9M
2013/14

9M
2012/13

Change

FY 2012/13

Revenue

9,214

8,665

6%

11,635

EBIT

2,047

2,699

(24%)

3,672

EBIT margin

22%

31%

(9) p.p.

32%

Special items

1,000

-

-

-






EBIT before special items

3,047

2,699

13%

3,672

EBIT margin before special items

33 %

31%

2 p.p.

32%


Sales performance by
business area

 9M
2013/14
DKKm

9M
2012/13
DKKm

Organic growth

Reported growth

Ostomy Care

3,764

3,613

8%

4%

Continence Care

3,288

3,029

11%

9%

Urology Care

898

844

10%

6%

Wound & Skin Care

1,264

1,179

10%

7%

Revenue

9,214

8,665

9%

6%

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ more than 9,000 people.

SOURCE Coloplast